NASDAQ
COGT

Cogent Biosciences Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Cogent Biosciences Inc Stock Price

Vitals

Today's Low:
$12
Today's High:
$12.485
Open Price:
$12.12
52W Low:
$4.412
52W High:
$18.07
Prev. Close:
$12.21
Volume:
525702

Company Statistics

Market Cap.:
$939.34 million
Book Value:
2.273
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$-121627000
Profit Margin:
0%
Return on Assets TTM:
-42.46%
Return on Equity TTM:
-72.04%

Company Profile

Cogent Biosciences Inc had its IPO on 2018-03-29 under the ticker symbol COGT.

The company operates in the Healthcare sector and Biotechnology industry. Cogent Biosciences Inc has a staff strength of 138 employees.

Stock update

Shares of Cogent Biosciences Inc opened at $12.12 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $12 - $12.49, and closed at $12.18.

This is a -0.25% slip from the previous day's closing price.

A total volume of 525,702 shares were traded at the close of the day’s session.

In the last one week, shares of Cogent Biosciences Inc have slipped by -6.16%.

Cogent Biosciences Inc's Key Ratios

Cogent Biosciences Inc has a market cap of $939.34 million, indicating a price to book ratio of 3.4617 and a price to sales ratio of 1320.6301.

In the last 12-months Cogent Biosciences Inc’s revenue was $0 with a gross profit of $-121627000 and an EBITDA of $-158356000. The EBITDA ratio measures Cogent Biosciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cogent Biosciences Inc’s operating margin was 0% while its return on assets stood at -42.46% with a return of equity of -72.04%.

In Q1, Cogent Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Cogent Biosciences Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.57 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cogent Biosciences Inc’s profitability.

Cogent Biosciences Inc stock is trading at a EV to sales ratio of 925.407 and a EV to EBITDA ratio of -4.5414. Its price to sales ratio in the trailing 12-months stood at 1320.6301.

Cogent Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$263.20 million
Total Liabilities
$21.12 million
Operating Cash Flow
$59.88 million
Capital Expenditure
$1.10 million
Dividend Payout Ratio
0%

Cogent Biosciences Inc ended 2024 with $263.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $263.20 million while shareholder equity stood at $223.56 million.

Cogent Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $21.12 million in other current liabilities, 71000.00 in common stock, $-449801000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $160.70 million and cash and short-term investments were $220.26 million. The company’s total short-term debt was $947,000 while long-term debt stood at $0.

Cogent Biosciences Inc’s total current assets stands at $226.27 million while long-term investments were $0 and short-term investments were $59.57 million. Its net receivables were $4.78 million compared to accounts payable of $4.17 million and inventory worth $0.

In 2024, Cogent Biosciences Inc's operating cash flow was $59.88 million while its capital expenditure stood at $1.10 million.

Comparatively, Cogent Biosciences Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$12.18
52-Week High
$18.07
52-Week Low
$4.412
Analyst Target Price
$22.33

Cogent Biosciences Inc stock is currently trading at $12.18 per share. It touched a 52-week high of $18.07 and a 52-week low of $18.07. Analysts tracking the stock have a 12-month average target price of $22.33.

Its 50-day moving average was $12.23 and 200-day moving average was $12.08 The short ratio stood at 7.11 indicating a short percent outstanding of 0%.

Around 0.2% of the company’s stock are held by insiders while 10946.4% are held by institutions.

Frequently Asked Questions About Cogent Biosciences Inc

The stock symbol (also called stock or share ticker) of Cogent Biosciences Inc is COGT

The IPO of Cogent Biosciences Inc took place on 2018-03-29

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$196.87
0.92
+0.47%
$10.61
0
0%
$10502.8
-32.1
-0.3%
$136.35
-9.15
-6.29%
$80.66
-0.99
-1.21%
$0.09
-0.01
-8.87%
$554.4
-11.65
-2.06%
Equinix Inc (EQIX)
$773.1
-1.52
-0.2%
Entegris Inc (ENTG)
$94.22
-1.29
-1.35%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Address

200 Cambridge Park Drive, Cambridge, MA, United States, 02140